tradingkey.logo

Australia's PainChek drops most in nearly 8 years on FDA approval delay

ReutersJun 5, 2025 4:13 AM

PainChek PCK.AX plunges as much as ~31% to A$0.038; marks biggest intraday pct drop since June 18, 2017

Stock hits lowest since May 7

Medical devices maker flags potential delay in U.S. FDA clearance for its pain assessment app

Expects clearance by mid-to-late September instead of the first half of 2025 anticipated earlier

About 14.3 mln shares traded in stock's busiest day since February 18, 2021

PCK last up 21.8%, taking YTD gains to 48.3%

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI